Core Viewpoint - The launch of Pemafibrate (brand name: Pailongda®) by Xinge Corporation on Alibaba Health marks the first official online availability of this selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) since its approval by the National Medical Products Administration in April 2025 [1][6]. Group 1: Product Overview - Pemafibrate is a next-generation selective PPARα modulator that has been available in Japan for nine years and is now being introduced to the Chinese market [1][6]. - The drug offers a combination of effective lipid-lowering properties and safety for liver and kidney functions, ensuring patients can purchase and use it with confidence [1][6]. Group 2: Clinical Significance - Hypertriglyceridemia is a common lipid disorder in China, with a prevalence rate of 15% to 22.4%, yet the treatment and control rates for affected patients are only 11.6% and 5.4%, respectively [5]. - The risk of microvascular events increases by 35% for every 1 mmol/L increase in triglyceride (TG) levels, and the risk of type 2 diabetes rises by 81% [5]. - Pemafibrate demonstrates a significant clinical advantage, with a molecular structure that activates PPARα over 2500 times more effectively than traditional fibrates [5]. Group 3: Efficacy and Guidelines - In clinical trials, a daily dose of 0.4 mg of Pemafibrate resulted in a triglyceride reduction of 51.8%, outperforming commonly used medications like fenofibrate [5]. - The drug is recognized in various authoritative guidelines, including the "Chinese Lipid Management Guidelines (2023)" and the European Society of Cardiology guidelines, confirming its regulatory compliance and efficacy [6]. Group 4: Target Population - Pemafibrate is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and can be used alone or in combination with statins [6].

Core Viewpoint - The announcement highlights a collaboration between Yuheng Pharmaceutical and Xinghe Pharmaceutical for the promotion of Pemabate Tablets, which is expected to enhance Yuheng's product line and competitiveness in the cardiovascular field [1]. Group 1 - Yuheng Pharmaceutical signed a co-promotion agreement with Xinghe Pharmaceutical on May 23, 2025, for Pemabate Tablets [1]. - The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and it can be automatically renewed thereafter [1]. - Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabate Tablets in designated areas and will pay service and promotional support fees [1]. Group 2 - Pemabate Tablets are the world's first novel high-selectivity PPARα modulator, primarily used to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1]. - This collaboration is expected to enrich Yuheng Pharmaceutical's product portfolio and strengthen its competitive position in the cardiovascular sector [1].